Soley Therapeutics closed a $200 million Series C to advance a portfolio of stress‑reducing drug candidates into the clinic, with a focus on oncology—including a lead AML program, SOL‑001—and plans for IND filings in 2026. Investors included the Doug Leone Family Fund and Breyer Capital. Soley’s platform centers on modulating cellular stress‑sensing pathways rather than single genetic drivers; the company said a meaningful portion of proceeds will fund IND enabling and early clinical work. For translational researchers and investors, the round highlights interest in upstream, systems‑level approaches to complex diseases where single‑target strategies have underperformed.